LXEO
Lexeo Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$4.89
+1.03%Aug 12, 2026, 00:00 UTC
Lexeo Therapeutics reported its Q2 2026 financial results, with a net loss of $25.9 million and diluted EPS of -$0.30, and cash, cash equivalents and investments of $234.2 million as of June 30, 2026.
Aug 5, 2026, 11:00 UTC
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lexeo Therapeutics for LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy, based on interim clinical data from an ongoing Phase I/II trial.
Source:Jun 15, 2026, 15:32 UTC
Lexeo Therapeutics announced a regulatory update regarding its pivotal SUNRISE-FA 2 trial for gene therapy candidate LX2006.
Source: